SAN FRANCISCO--(BUSINESS WIRE)--OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, today announced positive results from the recent Phase 2 study of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D). The double-blind, placebo-controlled, 12-week response adaptive randomization study investigated once-daily doses of 100 mg and 50 mg of ORP-101 vs. placebo. The 100 mg dose was more effective than placebo, whereas the 50 mg dose did not achieve statistical separation. Overall, ORP-101 was safe and well tolerated in all patients. Importantly, ORP-101 was also effective and safe in post-cholecystectomy IBS-D patients at the 100 mg dose throughout the treatment period.
SAN FRANCISCO--(BUSINESS WIRE)--OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced today that its ORP-101 molecule successfully passed a second interim futility analysis triggered by enrollment of 260 patients in its Phase 2 clinical trial for treatment of irritable bowel syndrome with diarrhea (IBS-D).
SAN FRANCISCO--(BUSINESS WIRE)--OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced today that its ORP-101 molecule successfully cleared its first interim futility analysis in a Phase 2 clinical trial for treatment of irritable bowel syndrome with diarrhea (IBS-D).
SAN FRANCISCO--(BUSINESS WIRE)--OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, today announced resumption of patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D).
OrphoMed, Inc., a clinical-stage biopharmaceutical company, today announced the presentation at Digestive Disease Week® (DDW) of Phase 1 data for its lead candidate ORP-101, being developed for the treatment of irritable bowel syndrome with diarrhea.
SAN FRANCISCO--(BUSINESS WIRE)--OrphoMed, Inc., a clinical-stage biopharmaceutical company, today announced the presentation at Digestive Disease Week® (DDW) of Phase 1 data for its lead candidate ORP-101, being developed for the treatment of irritable bowel syndrome with diarrhea.